Scientific Sessions 2024  /  Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations  /  Discussant: SCAN-MP
Logo

American Heart Association

  187
  0

Final ID:

Discussant: SCAN-MP

  • Alexander, Kevin  ( Stanford University , Palo Alto , California , United States )
    • Author Disclosures:
    Kevin Alexander: DO have relevant financial relationships ; Consultant:Arbor Biotechnologies:Active (exists now) ; Consultant:Bristol Myers Squibb:Past (completed) ; Consultant:Prothena:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Intellia:Past (completed) ; Consultant:Alnylam:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations

Monday, 11/18/2024 , 09:45AM - 11:00AM

Featured Science

More abstracts on this topic:
Danon Disease Phase 1 RP-A501 Results: The First Single-Dose Intravenous Gene Therapy with Recombinant Adeno-Associated Virus (AAV9:LAMP2B) for a Monogenic Cardiomyopathy

Greenberg Barry, Coggins Matthew, Schwartz Jonathan, Rossano Joseph, Taylor Matthew, Colan Steven, Adler Eric, Ricks David, Yarabe Paul, Battiprolu Pavan, Shah Guarav, Patel Kinnari

Mavacamten Treatment in Patients with Obstructive HCM Referred for Septal Reduction Therapy: 128-Week Results from VALOR-HCM Trial

Desai Milind, Nissen Steven

More abstracts from these authors:
CRISPR Quagmire: Weighing the Risks of Gene Therapies

Mammen Pradeep, Alexander Kevin

Disparities in the Management and Outcomes of Cardiac Amyloidosis in Underrepresented Populations. -how can we bridge the gaps? 10 minutes

Bullock-palmer Renee, Alexander Kevin

You have to be authorized to contact abstract author. Please, Login
Not Available